Welcome to the international HTA database

Showing [24456 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	NIHR Health Services and Delivery Research programme	Emergency medical services streaming enabled evaluation in trauma: the SEE-IT Feasibility RCT
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cimicifuga: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Meropenem/vaborbactam (bacterial infections, several therapeutic indications) - Assessment in accordance with § 35a (1c) Social Code Book (SGB) V ]
2025	NIHR Health Technology Assessment programme	Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Prevention of hypersensitivity reactions to intravascular contrast media during medical imaging in adults]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Clonidine: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025	NIHR Health Technology Assessment programme	Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025	National Institute for Health and Care Excellence (NICE)	Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1068
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Gabapentin: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – Second addendum to Project H23-03]
2025	National Institute for Health and Care Excellence (NICE)	Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1065
2025	National Institute for Health and Care Excellence (NICE)	Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1064
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cognitive behavioural therapy: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025	NIHR Health Services and Delivery Research programme	Improving the experience of health services for trans and gender-diverse young people and their families: an exploratory qualitative study
2025	National Institute for Health and Care Excellence (NICE)	Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment. NICE technology appraisal guidance 1063
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[SSRI/SSNRI: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Proton therapy in cancer treatment: evaluation of safety, efficacy, effectiveness, and efficiency]
2025	National Institute for Health and Care Excellence (NICE)	Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor. NICE technology appraisal guidance 1062
2025	National Institute for Health and Care Excellence (NICE)	Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1060
2025	Agency for Care Effectiveness (ACE)	Antibacterial envelope for implantable neurostimulator infection control
2025	National Institute for Health and Care Excellence (NICE)	Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 1059
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of the aortic stent graft (The GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System) for thoracic aortic aneurysm and complicated type B aortic dissection]
2025	Agency for Care Effectiveness (ACE)	Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025	National Institute for Health and Care Excellence (NICE)	Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal). NICE technology appraisal guidance 1061
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Tumor biomarkers related to managing people with prostate cancer]
2025	Agency for Care Effectiveness (ACE)	Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025	NIHR Health Technology Assessment programme	Effects of pharmacological and non-pharmacological interventions for the management of sleep problems in people with fibromyalgia: a multi-methods evidence synthesis
2025	NIHR Health Technology Assessment programme	Stepping into day treatment approach versus inpatient treatment for adults with anorexia nervosa: the DAISIES RCT
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Algorithm for the management of low back pain with or without radicular pain]
2025	NIHR Health Technology Assessment programme	Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Breast cancer treatment algorithm]
2025	National Institute for Health and Care Excellence (NICE)	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. NICE highly specialised technologies guidance 33
2025	NIHR Health Technology Assessment programme	Clinical and cost-effectiveness of detailed anomaly ultrasound screening in the first trimester: a mixed-methods study
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Adaptive deep brain stimulation in Parkinson's disease]
2025	NIHR Health Services and Delivery Research programme	Intersecting factors of disadvantage and discrimination and their effect on daily life during the coronavirus pandemic: the CICADA-ME mixed-methods study
2025	NIHR Health Services and Delivery Research programme	The spiritual needs and care of children and young people with life-threatening or life-shortening conditions, and parents (SPARK): a mixed-method investigation
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Lung cancer treatment algorithm]
2025	National Institute for Health and Care Excellence (NICE)	Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Digital technology promoting health for children and adolescents - an evidence map]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Confirmed trichomonas vaginalis infection: pharmacological treatment]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Interventions to formal caregivers for increased patient safety]
2025	NIHR Health Services and Delivery Research programme	Understanding and addressing factors affecting carers’ mental health during end-of-life caregiving: synopsis of meta synthesis of literature and stakeholder collaboration
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[A look at connected objects and their integration into remote monitoring]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Newborn screening for Metachromatic leukodystrophy (MLD)]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[International experiences in home hospitalization: challenges and possible solutions]
2025	NIHR Health Technology Assessment programme	Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs)
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Accuracy of diagnostic algorithms for suspected or elevated risk of ovarian cancer]
2025	NIHR Health Services and Delivery Research programme	Cancer in English prisons: a mixed-methods study of diagnosis, treatment, care costs and patient and staff experiences
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of tenapanor (Phozevel)
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Initiating a diagnostic and therapeutic measure in a person with signs and symptoms of pharyngitis/tonsillitis]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Psychometric properties for instruments used to measure core outcomes for provoked vestibulodynia]
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of inclisiran (Leqvio)
2025	Health Information and Quality Authority (HIQA)	Paediatric early warning systems in emergency settings: protocol for a systematic review of clinical guidelines
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Interventions for behavioural change in the aim of promoting health and preventing disability in the elderly]
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of semaglutide (Wegovy)
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Pharmacological treatment of polycystic ovary syndrome - health and quality of life in the short and long term]
2025	NIHR Health Services and Delivery Research programme	After the disruptive innovation: How remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glofitamab (DLBCL, combination with gemcitabine and oxaliplatin) – Benefit assessment according to §35a Social Code Book V]
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Ritlecitinib tosylate (Litfulo)]
2025	NIHR Health Services and Delivery Research programme	Barriers to and outcomes of unspecified kidney donation in the UK: BOUnD, a mixed-methods study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glofitamab (DLBCL, monotherapy, third line or later) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Services and Delivery Research programme	Enhancing referrals to child and adolescent mental health services: the EN-CAMHS mixed-methods study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Technology Assessment programme	Interventions that challenge established and accepted clinical practice: lessons learnt from a process evaluation of the STOP-APE trial
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025	Agency for Care Effectiveness (ACE)	Mavacamten for treating obstructive hypertrophic cardiomyopathy
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Technology Assessment programme	Learnings from the establishment and delivery of the UK Collaborative Paediatric Palliative Care Research Network
2025	Agency for Care Effectiveness (ACE)	Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Garadacimab (hereditary angioedema) – Addendum to Project A25-41]
2025	Swiss Federal Office of Public Health (FOPH)	Magnesium supplements for muscle cramps and for the prevention of recurrent urinary tract stones
2025	NIHR Health Technology Assessment programme	Establishing palliative care research partnerships in Northern Ireland
2025	Agency for Care Effectiveness (ACE)	Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[IQWiG benefit assessments based on systematic reviews: A comparative overview]
2025	Swiss Federal Office of Public Health (FOPH)	Point-of-care diagnostic tests
2025	NIHR Health Services and Delivery Research programme	Clinical and cost-effectiveness of paramedics working in general practice: a mixed-methods realist evaluation
2025	Agency for Care Effectiveness (ACE)	Atogepant and rimegepant for prophylaxis of migraine
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Perinatal pathway: supporting women in a handicap situation related to a physical disability, an intellectual disability or autism]
2025	Swiss Federal Office of Public Health (FOPH)	Multigene-expression tests for breast cancer
2025	NIHR Health Services and Delivery Research programme	Optimisation of the deployment of automated external defibrillators in public places in England
2025	Agency for Care Effectiveness (ACE)	Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
2025	NIHR Health and Social Care Delivery Program	Optimising the delivery and impacts of interventions to improve hospital doctors’ workplace wellbeing in the NHS: The Care Under Pressure 3 realist evaluation study
2025	NIHR Health Technology Assessment programme	Understanding the effectiveness and underlying mechanisms of lifestyle modification interventions in adults with learning disabilities: a mixed-methods systematic review
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Food allergen-specific IgG4 (immunoglobulin G4) measurement by immunoassay]
2025	National Institute for Health and Care Excellence (NICE)	Guselkumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 1094
2025	National Institute for Health and Care Excellence (NICE)	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Blood levels testing of imatinib and its active metabolite by high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS)]
2025	National Institute for Health and Care Excellence (NICE)	Guselkumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 1095
2025	National Institute for Health and Care Excellence (NICE)	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over. NICE technology appraisal guidance 1044
2025	National Institute for Health and Care Excellence (NICE)	Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over. NICE technology appraisal guidance 1093
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Asynchronous teledermatology as a mechanism for triage and patient referral between primary and specialty care and to support the diagnosis of dermatologic conditions]
2025	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer. NICE technology appraisal guidance 1092
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1042
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of genetic tests related to hearing loss and their role in neonatal population screening]
2025	National Institute for Health and Care Excellence (NICE)	Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments. NICE technology appraisal guidance 1091
2025	National Institute for Health and Care Excellence (NICE)	Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over. NICE technology appraisal guidance 1033
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma. NICE technology appraisal guidance 1090
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1038